$LH

Wilkinson Peter J sold $439K of LH

Wilkinson Peter J (SVP, Chief Accounting Officer) sold 1,420 shares of LABCORP HOLDINGS INC. (LH) at an average of $309.23 ($309.22–$309.23, $0.44M total) across 2 trades on 2026-08-03.

Original reporting
SEC EDGAR · Wilkinson Peter J
Published Aug 5, 2026, 3:17 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 3:24 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$LH
Neutral
low confidence
Mentioned
$LH
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LHNeutralLow
01

Why it matters

The only new information is the specific open-market sale size, price range, and post-transaction holdings; it does not change LH’s operating outlook.

02

Market read

Traders may note insider selling, but there is no fundamental catalyst or guidance change tied to the filing.

03

What to watch

Insider sales are common and often not predictive; the disclosure lacks context on total holdings, compensation timing, or whether other insiders are buying.

Relevance 4/10Novelty 2/10Timing: filed 2026-08-05 after-hours/late session window (per timestamp)

Background

The article is an SEC Form 4 insider transaction report for Labcorp Holdings (LH) by Peter J. Wilkinson, SVP and Chief Accounting Officer.

Company-level read

Ticker impact

$LHNeutralLow confidence
Context

SEC Form 4 shows LH CFO Wilkinson sold 1,420 shares in open-market trades at about $309.23 on 2026-08-03.

Expected impact

Low likelihood of a sustained price move solely from this Form 4.

Evidence & confidence

The filing is an open-market sale, not a buy, and it does not include new company guidance, contracts, or regulatory actions.

Market effects

None.

None.

None.

Counterpoint

The sale may be driven by diversification or tax planning rather than a bearish view, especially without a 10b5-1 plan.

Key entities

  • LABCORP HOLDINGS INC.

    Subject of the Form 4 insider transaction disclosure.

  • Wilkinson Peter J

    SVP, Chief Accounting Officer who sold shares in open-market trades.

Related articles

$LHMed

Approved PTEN IHC Companion Diagnostic for Prostate Cancer

Labcorp said it has nationwide availability of Roche’s Ventana PTEN (SP218) RxDx immunohistochemistry companion diagnostic, FDA approved to detect PTEN protein loss in prostate adenocarcinoma. The result helps identify patients eligible for AstraZeneca’s TRUQAP (capivasertib) plus abiraterone acetate and prednisone. Labcorp says it supports personalized treatment decisions via its lab network.

$LHMed

LABCORP HOLDINGS 2026: Revenue $3.73B, EPS $3.64— 10-Q Summary

Labcorp Holdings (LH) reported Q2 2026 revenue of $3.73B and diluted EPS of $3.64, up from $3.53B and $2.84 a year earlier, according to its 10-Q. The company cited higher test utilization, price and mix gains, and margin expansion, plus 4.2% organic growth and acquisition contributions. It also increased capital spending and completed acquisitions.

$LHMed

Labcorp launches FDA-approved PTEN test for prostate cancer

Labcorp (NYSE:LH) said the FDA-approved Roche VENTANA PTEN (SP218) RxDx Assay is now available nationwide. The test detects PTEN protein loss in prostate adenocarcinoma tissue to identify patients who may qualify for AstraZeneca’s TRUQAP (capivasertib) with abiraterone and prednisone, according to Labcorp. The assay is offered via Labcorp’s lab network.

$LHMedAI 9/10

Labcorp (LH) Q2 2026 Earnings Call Transcript

Labcorp (LH) reported Q2 2026 enterprise revenue of $3.7B, up 5.8% YoY, with adjusted EPS of $4.99, up 14.9%. Adjusted operating margin rose to 15.8%. Free cash flow was $314M. The company raised full-year guidance for revenue and adjusted EPS, citing Diagnostics and Central Laboratories strength, and noted ACA headwinds.

$LHHighAI 9/10

Labcorp (LH) Q2 2026 Earnings Call Transcript

Thursday, July 30, 2026 at 9:00 a.m. ET CALL PARTICIPANTS Senior Vice President, Investor Relations - Dewey Steadman Chairman and Chief Executive Officer - Adam Schechter Executive Vice President and Chief Financial Officer - Julia Wang TAKEAWAYS Enterprise Revenue -- $3.7 billion, up 5.8% year over year, driven by 4.2% organic growth and 1.2% contribution from net acquisitions.